Position in RIGL
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$62,239
+$17,839 QoQ
Shares Held
1,591
-47.0% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#109
of 155 holders
Holding Since
Jun 2023
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RIGL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026NATIXIS holds $65,699,213 across 42 Biotechnology names. RIGL ranks #32 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
59,095 | $29,354,259 | |
| 2 | CORT |
Corcept Therapeutics Inc
|
109,905 | $9,556,239 | |
| 3 | EXEL |
Exelixis, Inc.
|
121,041 | $6,585,840 | |
| 4 | MRNA |
Moderna, Inc.
|
66,370 | $4,647,891 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
6,599 | $4,114,740 | |
| 6 | CAI |
Caris Life Sciences, Inc.
|
124,716 | $2,222,439 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
8,467 | $1,585,699 | |
| 8 | PTGX |
Protagonist Therapeutics, Inc
|
7,776 | $953,182 |
All Filings in RIGL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $62,239 | 1,591 | Shares | Sole | 2026-08-13 | |
| 2024-03-31 | $44,400 | 30,000 | Shares | Sole | 2024-05-13 | |
| 2023-12-31 | $54,375 | 37,500 | Shares | Sole | 2024-02-13 | |
| 2023-09-30 | $40,500 | 37,500 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $73,847 | 57,246 | Shares | Sole | 2023-08-11 | |
| No filing history on record for this holder in this stock. | ||||||